Pa. Health Dept. Announces New 2,251 Coronavirus Cases Over Last Two Days After Technical Delay

By: KDKA-TV News Staff

HARRISBURG (KDKA) — The Pennsylvania Department of Health is reporting 2,251 new cases of Coronavirus and 17 additional deaths over the last two days.

The state reports there was a “technical issue” that led to a delay in reporting Saturday’s coronavirus update. Recently, the Pennsylvania Department of Health had shifted to publishing coronavivrus updates Monday through Saturday, with Sunday’s and Monday’s updates included on Monday. Today’s update is reflective of data from Saturday and Sunday.

The statewide total number of cases has risen to 163,535 since Friday’s report, according to the state’s data.

The Health Department says all 67 counties in Pennsylvania have had cases of COVID-19. Current patients are either in isolation at home or being treated at the hospital.

The statewide death toll has risen to 8,216.

There are 1,931,635 patients across the state who have tested negative to date.

The state Health

Read More

A self-inflicted crisis in biomedical research could delay discoveries and cures for years



A self-inflicted crisis in biomedical research could delay discoveries and cures for years


© Getty Images
A self-inflicted crisis in biomedical research could delay discoveries and cures for years

American medical research, a crown jewel of the world scientific community, faces a profound crisis in the age of COVID-19. Without policy changes by the federal government, the academic biomedical research sector could be hobbled for years to come and could lose its competitive edge to other nations.

Over the past six months, medical researchers have been battered by a triple blow. First, most clinical trials in the United States came to a halt to protect participants and staff from COVID-19 infection. Then, academic hospitals and medical centers, financially crippled by the pandemic, dramatically cut back on research funding. Finally, the Trump Administration stopped issuing visas to foreign scientists, cutting off a wellspring of talent on which American research teams depend.

“It is the most turbulent time for academic biomedical and clinical research you

Read More

World Health Organization is wrong on dental care: Do not delay preventive exams

Ever since the advent of HIV in the 1980s, U.S. dental practices have followed state-of-the-art infection control standards. These are designed to protect patients and dental providers from infectious and contagious diseases, and they are very effective.

COVID-19 has presented the opportunity to revisit and amplify those standards. Even when routine care was suspended, several of our School of Dentistry clinics have continuously provided urgent care. We have compiled a great deal of expertise on providing safe, high-quality care during the pandemic and shared it with dental professionals via free webinars. We have continuously updated our clinical protocols as we learn more about this virus and how to prevent its spread. We know the dental community more broadly is doing the same.

Patients should know that there has not been one single reported case of COVID-19 transmission associated with dental care — none from patient to patient, patient to provider

Read More

Novartis faces delay after FDA asks for another Zolgensma study

By John Miller

ZURICH (Reuters) – Novartis’s bid to expand its $2.1 million-per-patient gene therapy Zolgensma to more spinal muscular atrophy patients faces a possible delay after U.S. regulators requested another study in older children getting the drug via a spinal infusion.

Novartis, whose shares fell 1% in early Wednesday trading, said the U.S. Food and Drug Administration’s (FDA) request for an additional study was not linked to an ongoing safety hold on a Zolgensma trial after possible neurological damage in primates emerged last year.

The Basel-based company also said the move to satisfy the FDA would not affect the therapy’s existing approval in babies up to two years with the rare genetic condition.

Still, an analyst said the FDA’s request for more data – from children aged 2 to 5 years getting Zolgensma via spinal infusion – would delay Novartis’s efforts to expand approval to at least late 2023,

Read More